Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
34
TLSA Quote, Financials, Valuation and Earnings
Last price:
$1.28
Seasonality move
:
8.1%
Day range:
$1.34 - $1.40
52-week range:
$0.73 - $2.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,803.69x
P/B ratio:
65.31x
Volume:
65.2K
Avg. volume:
269.9K
1-year change:
51.75%
Market cap:
$178.1M
Revenue:
--
EPS (TTM):
-$0.13
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | $8.01 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -- | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
$1.6M | -$0.15 | 700.8% | -12.5% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd.
|
$1.40 | $8.01 | $178.1M | -- | $0.00 | 0% | 2,803.69x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.29 | $17.94 | $1.1M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$2.15 | $104.00 | $8.9M | -- | $0.00 | 0% | -- |
|
OXBDF
Oxford Biomedica Plc
|
$10.90 | -- | $1.3B | -- | $0.00 | 0% | 5.91x |
|
SLNCF
Silence Therapeutics Plc
|
$1.60 | -- | $226.7M | -- | $0.00 | 0% | 112.71x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -0.113 | -- | -- |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.310 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.482 | 0.95% | 4.03x |
|
OXBDF
Oxford Biomedica Plc
|
37.49% | 2.408 | -- | 1.99x |
|
SLNCF
Silence Therapeutics Plc
|
0.25% | 4.622 | 0.09% | 5.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | -- | -- |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -90.47% | -120.93% | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
-$20.5K | -$23.7M | -101.67% | -101.79% | -14881.13% | -$11M |
Tiziana Life Sciences Ltd. vs. Competitors
-
Which has Higher Returns TLSA or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Tiziana Life Sciences Ltd.'s net margin of --. Tiziana Life Sciences Ltd.'s return on equity of -- beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital TLSATiziana Life Sciences Ltd.-- -- -- BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About TLSA or BDRX?
Tiziana Life Sciences Ltd. has a consensus price target of $8.01, signalling upside risk potential of 472.15%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 13686.92%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Tiziana Life Sciences Ltd., analysts believe Biodexa Pharmaceuticals Plc is more attractive than Tiziana Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TLSATiziana Life Sciences Ltd.1 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is TLSA or BDRX More Risky?
Tiziana Life Sciences Ltd. has a beta of 0.186, which suggesting that the stock is 81.437% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.
-
Which is a Better Dividend Stock TLSA or BDRX?
Tiziana Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences Ltd. pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSA or BDRX?
Tiziana Life Sciences Ltd. quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Tiziana Life Sciences Ltd.'s net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Tiziana Life Sciences Ltd.'s price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences Ltd. is 2,803.69x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSATiziana Life Sciences Ltd.2,803.69x -- -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns TLSA or NCNA?
NuCana Plc has a net margin of -- compared to Tiziana Life Sciences Ltd.'s net margin of --. Tiziana Life Sciences Ltd.'s return on equity of -- beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital TLSATiziana Life Sciences Ltd.-- -- -- NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About TLSA or NCNA?
Tiziana Life Sciences Ltd. has a consensus price target of $8.01, signalling upside risk potential of 472.15%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 969596.97%. Given that NuCana Plc has higher upside potential than Tiziana Life Sciences Ltd., analysts believe NuCana Plc is more attractive than Tiziana Life Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TLSATiziana Life Sciences Ltd.1 0 0 NCNANuCana Plc0 1 0 -
Is TLSA or NCNA More Risky?
Tiziana Life Sciences Ltd. has a beta of 0.186, which suggesting that the stock is 81.437% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.66%.
-
Which is a Better Dividend Stock TLSA or NCNA?
Tiziana Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences Ltd. pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSA or NCNA?
Tiziana Life Sciences Ltd. quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Tiziana Life Sciences Ltd.'s net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Tiziana Life Sciences Ltd.'s price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences Ltd. is 2,803.69x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSATiziana Life Sciences Ltd.2,803.69x -- -- -- NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns TLSA or OXBDF?
Oxford Biomedica Plc has a net margin of -- compared to Tiziana Life Sciences Ltd.'s net margin of --. Tiziana Life Sciences Ltd.'s return on equity of -- beat Oxford Biomedica Plc's return on equity of -120.93%.
Company Gross Margin Earnings Per Share Invested Capital TLSATiziana Life Sciences Ltd.-- -- -- OXBDFOxford Biomedica Plc-- -- $140.3M -
What do Analysts Say About TLSA or OXBDF?
Tiziana Life Sciences Ltd. has a consensus price target of $8.01, signalling upside risk potential of 472.15%. On the other hand Oxford Biomedica Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Tiziana Life Sciences Ltd. has higher upside potential than Oxford Biomedica Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Oxford Biomedica Plc.
Company Buy Ratings Hold Ratings Sell Ratings TLSATiziana Life Sciences Ltd.1 0 0 OXBDFOxford Biomedica Plc0 0 0 -
Is TLSA or OXBDF More Risky?
Tiziana Life Sciences Ltd. has a beta of 0.186, which suggesting that the stock is 81.437% less volatile than S&P 500. In comparison Oxford Biomedica Plc has a beta of 1.082, suggesting its more volatile than the S&P 500 by 8.226%.
-
Which is a Better Dividend Stock TLSA or OXBDF?
Tiziana Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oxford Biomedica Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences Ltd. pays -- of its earnings as a dividend. Oxford Biomedica Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSA or OXBDF?
Tiziana Life Sciences Ltd. quarterly revenues are --, which are smaller than Oxford Biomedica Plc quarterly revenues of --. Tiziana Life Sciences Ltd.'s net income of -- is lower than Oxford Biomedica Plc's net income of --. Notably, Tiziana Life Sciences Ltd.'s price-to-earnings ratio is -- while Oxford Biomedica Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences Ltd. is 2,803.69x versus 5.91x for Oxford Biomedica Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSATiziana Life Sciences Ltd.2,803.69x -- -- -- OXBDFOxford Biomedica Plc5.91x -- -- --
-
Which has Higher Returns TLSA or SLNCF?
Silence Therapeutics Plc has a net margin of -- compared to Tiziana Life Sciences Ltd.'s net margin of -13181.13%. Tiziana Life Sciences Ltd.'s return on equity of -- beat Silence Therapeutics Plc's return on equity of -101.79%.
Company Gross Margin Earnings Per Share Invested Capital TLSATiziana Life Sciences Ltd.-- -- -- SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M -
What do Analysts Say About TLSA or SLNCF?
Tiziana Life Sciences Ltd. has a consensus price target of $8.01, signalling upside risk potential of 472.15%. On the other hand Silence Therapeutics Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Tiziana Life Sciences Ltd. has higher upside potential than Silence Therapeutics Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings TLSATiziana Life Sciences Ltd.1 0 0 SLNCFSilence Therapeutics Plc1 0 0 -
Is TLSA or SLNCF More Risky?
Tiziana Life Sciences Ltd. has a beta of 0.186, which suggesting that the stock is 81.437% less volatile than S&P 500. In comparison Silence Therapeutics Plc has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.438%.
-
Which is a Better Dividend Stock TLSA or SLNCF?
Tiziana Life Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Silence Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tiziana Life Sciences Ltd. pays -- of its earnings as a dividend. Silence Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSA or SLNCF?
Tiziana Life Sciences Ltd. quarterly revenues are --, which are smaller than Silence Therapeutics Plc quarterly revenues of $159K. Tiziana Life Sciences Ltd.'s net income of -- is lower than Silence Therapeutics Plc's net income of -$21M. Notably, Tiziana Life Sciences Ltd.'s price-to-earnings ratio is -- while Silence Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tiziana Life Sciences Ltd. is 2,803.69x versus 112.71x for Silence Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSATiziana Life Sciences Ltd.2,803.69x -- -- -- SLNCFSilence Therapeutics Plc112.71x -- $159K -$21M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
